We’re getting excited for AACR IO 2026 in Los Angeles (Feb 18–21)! Bhardwaj Lab members will be giving talks and presenting posters. Please come find us there to chat about dendritic cells, immunotherapy, and cancer vaccines. @theaacr.bsky.social www.aacr.org/meeting/aacr...

Preprint: Targeting Neoantigens Conserved Across Organs and Species Overcomes Tumor Immune Escape @bhardwajlab.bsky.social @sinaiimmuno.bsky.social
papers.ssrn.com/sol3/papers....

AACR IO: Revolutionizing Treatment through Immunotherapy The AACR’s immuno-oncology meeting in Los Angeles, Feb. 23-26, 2025, brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.

The inaugural AACR IO Conference on Discovery and Innovation in Cancer Immunology takes place February 23-26 in Los Angeles. Learn why Dr. Antoni Ribas says #AACRIO25 is “the must-attend immuno-oncology event of the year." 
www.aacr.org/about-the-aa... 
#AACRStories

3. What the field needs next to move from “promising trials” → standard of care.
Kudos to first author Sayali Onkar + co-authors Mansi Saxena and Cansu Cimen Bozkus.
Hope you find this review insightful and energizing for the future of cancer vaccines. Read here: www.cell.com/cell-reports... (4/4)

1. Why vaccine monotherapy often underperforms in advanced disease and the growing promise of combinations (especially with immune checkpoint inhibitors)
2. Key bottlenecks: neoantigen prediction, antigen selection, manufacturing timelines (3/4)

Over the past decade, therapeutic cancer vaccines—especially neoantigen-based approaches—have rapidly evolved thanks to advances in sequencing, antigen prediction, and delivery platforms. In this review, we synthesize the latest clinical trial data and discuss: (2/4)

Pipe dream to pipeline: Journey of cancer vaccines and the road ahead Onkar et al. discuss the current landscape of therapeutic cancer vaccines in the context of recent clinical trials, with a special focus on neoantigen vaccines. They also highlight challenges and scop...

Excited to share our review "Pipe dream to Pipeline: Journey of cancer vaccines and the road ahead" that is now published in Cell Reports Medicine by Cell Press! (1/4)

Antigen presentation requirements for effective cDC1-based cancer immunotherapy https://www.biorxiv.org/content/10.64898/2026.01.24.701412v1

Submit a clinical trial or late-breaking abstract by January 20 for the AACR IO Conference on Discovery and Innovation in Cancer Immunology (February 18-21, 2026; Los Angeles), chaired by Nina Bhardwaj and Antoni Ribas. Learn more:
buff.ly/bb9lwPV
#AACRIO26

New year, new Bluesky account! We’re the Bhardwaj Lab at @mountsinainyc.bsky.social studying cancer immunology and immunotherapy. Here’s a snapshot of some of our team from our New Year kickoff party. Looking forward to connecting and sharing papers, preprints and lab updates.